Table of Contents Author Guidelines
Genetics Research International
Volume 2017, Article ID 9532471, 7 pages
https://doi.org/10.1155/2017/9532471
Research Article

Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?

1Laboratory of Genetics and Molecular Pathology, Medical School, University Hassan II, Casablanca, Morocco
2Department of Cardiology, University Hospital Center Hassan II, Fes, Morocco
3Department of Cardiology, University Hospital Center Ibn Rochd, Casablanca, Morocco

Correspondence should be addressed to Hind Hassani Idrissi; rf.liamtoh@dnih-issirdi-inassah

Received 17 October 2016; Revised 3 January 2017; Accepted 12 January 2017; Published 5 February 2017

Academic Editor: Norman A. Doggett

Copyright © 2017 Hind Hassani Idrissi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. H. Guyatt, D. J. Cook, R. Jaeschke, S. G. Pauker, and H. J. Schünemann, “Grades of recommendation for antithrombotic agents: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. B. King III, S. C. Smith Jr., J. W. Hirshfeld Jr. et al., “2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on behalf of the 2005 Writing Committee,” Circulation, vol. 117, no. 2, pp. 261–295, 2007. View at Publisher · View at Google Scholar
  3. F. Marín, R. González-Conejero, P. Capranzano, T. A. Bass, V. Roldán, and D. J. Angiolillo, “Pharmacogenetics in cardiovascular antithrombotic therapy,” Journal of the American College of Cardiology, vol. 54, no. 12, pp. 1041–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives,” Journal of the American College of Cardiology, vol. 49, no. 14, pp. 1505–1516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. T. H. Wang, D. L. Bhatt, and E. J. Topol, “Aspirin and clopidogrel resistance: an emerging clinical entity,” European Heart Journal, vol. 27, no. 6, pp. 647–654, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W. E. Evans and H. L. McLeod, “Pharmacogenomics—drug disposition, drug targets, and side effects,” New England Journal of Medicine, vol. 348, no. 6, pp. 538–549, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Taubert, N. von Beckerath, G. Grimberg et al., “Impact of P-glycoprotein on clopidogrel absorption,” Clinical Pharmacology and Therapeutics, vol. 80, no. 5, pp. 486–501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1895–1900, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-W. Suh, B.-K. Koo, S.-Y. Zhang et al., “Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel,” CMAJ, vol. 174, no. 12, pp. 1715–1722, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-S. Hulot, A. Bura, E. Villard et al., “Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects,” Blood, vol. 108, no. 7, pp. 2244–2247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Von Beckerath, O. Von Beckerath, W. Koch, M. Eichinger, A. Schömig, and A. Kastrati, “P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose,” Blood Coagulation and Fibrinolysis, vol. 16, no. 3, pp. 199–204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. I. Lev, R. T. Patel, S. Guthikonda, D. Lopez, P. F. Bray, and N. S. Kleiman, “Genetic polymorphisms of the platelet receptors P2Y12, P2Y1 and GP IIIa and response to aspirin and clopidogrel,” Thrombosis Research, vol. 119, no. 3, pp. 355–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Dropinski, J. Musial, B. Jakiela, W. Wegrzyn, M. Sanak, and A. Szczeklik, “Anti-thrombotic action of clopidogrel and PIA1/A2 polymorphism of β3 integrin in patients with coronary artery disease not being treated with aspirin,” Thrombosis and Haemostasis, vol. 94, no. 6, pp. 1300–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. H. Hassani Idrissi, W. Hmimech, N. El Khorb, H. Akoudad, R. Habbal, and S. Nadifi, “Association of the C3435T Multi-Drug Resistance gene-1 (MDR-1) polymorphism with Clopidogrel resistance among Moroccan Acute Coronary Syndromes (ACS) patients,” Journal of Thrombosis and Circulation, vol. 2, article 115, 2016. View at Google Scholar
  15. M. V. Holmes, P. Perel, T. Shah, A. D. Hingorani, and J. P. Casas, “CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 306, no. 24, 2011. View at Google Scholar
  16. L. A. Malek, B. Kisiel, M. Spiewak et al., “Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel,” Circulation Journal, vol. 72, no. 7, pp. 1165–1169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., “Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease,” Thrombosis Research, vol. 116, no. 6, pp. 491–497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Cuisset, C. Frere, J. Quilici et al., “Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome,” Thrombosis Research, vol. 120, no. 6, pp. 893–899, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Hollopeter, H.-M. Jantzen, D. Vincent et al., “Identification of the platelet ADP receptor targeted by antithrombotic drugs,” Nature, vol. 409, no. 6817, pp. 202–207, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Malinin, A. Pokov, M. Spergling et al., “Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study,” Thrombosis Research, vol. 119, no. 3, pp. 277–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Prabhakaran, K. R. Wells, V. H. Lee, C. A. Flaherty, and D. K. Lopes, “Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting,” American Journal of Neuroradiology, vol. 29, no. 2, pp. 281–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Y. Gasparyan, “Aspirin and clopidogrel resistance: methodological challenges and opportunities,” Vascular Health and Risk Management, vol. 6, no. 1, pp. 109–112, 2010. View at Google Scholar · View at Scopus
  23. S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Research, vol. 16, no. 3, article 1215, 1988. View at Publisher · View at Google Scholar · View at Scopus
  24. S. C. Smith Jr., T. E. Feldman, J. W. Hirshfeld Jr. et al., “ACC/AHA/SCAI 2005 guideline update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 guidelines for Percutaneous Coronary Intervention),” Journal of the American College of Cardiology, vol. 47, no. 1, pp. e1–e121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. J. Bouman, J. W. van Werkum, G. Rudež et al., “The relevance of P2Y12-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up,” Thrombosis and Haemostasis, vol. 107, no. 1, pp. 189–191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Zoheir, S. A. Elhamid, N. Abulata, M. E. Sobky, D. Khafagy, and A. Mostafa, “P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting,” Blood Coagulation and Fibrinolysis, vol. 24, no. 5, pp. 525–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Simon, C. Verstuyft, M. Mary-Krause et al., “Genetic determinants of response to clopidogrel and cardiovascular events,” New England Journal of Medicine, vol. 360, no. 4, pp. 363–375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. O. V. Sirotkina, A. M. Zabotina, O. A. Berkovich, E. A. Bazhenova, T. V. Vavilova, and A. L. Shvartsman, “Genetic variants of platelet ADP receptor P2Y12 associated with changed platelet functional activity and development of cardiovascular diseases,” Genetika, vol. 45, no. 2, pp. 247–253, 2009. View at Google Scholar · View at Scopus
  29. P. Fontana, A. Dupont, S. Gandrille et al., “Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects,” Circulation, vol. 108, no. 8, pp. 989–995, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. D. Nordeen, A. V. Patel, and R. M. Darracott, “Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications,” Journal of Vascular and Interventional Neurology, vol. 6, no. 1, pp. 26–34, 2013. View at Google Scholar
  31. J. S. Berger, M. C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, and D. L. Brown, “Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials,” Journal of the American Medical Association, vol. 295, no. 3, pp. 306–316, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Boersma, R. A. Harrington, D. J. Moliterno et al., “Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials,” The Lancet, vol. 359, no. 9302, pp. 189–198, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Jochmann, K. Stangl, E. Garbe, G. Baumann, and V. Stangl, “Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases,” European Heart Journal, vol. 26, no. 16, pp. 1585–1595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. L. Hetherington, R. K. Singh, D. Lodwick, J. R. Thompson, A. H. Goodall, and N. J. Samani, “Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 252–257, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Cavallari, E. Trabetti, G. Malerba et al., “Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease,” BMC Medical Genetics, vol. 8, article no. 59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. I. T. Schettert, A. C. Pereira, N. H. Lopes, W. A. Hueb, and J. E. Krieger, “Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease,” Thrombosis Research, vol. 118, no. 6, pp. 679–683, 2006. View at Publisher · View at Google Scholar · View at Scopus